Truist Financial’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$149M Sell
754,121
-15,219
-2% -$2.93M 0.2% 98
2025
Q4
$141M Buy
769,340
+268,954
+54% +$47.2M 0.19% 104
2025
Q3
$76.8M Buy
500,386
+93,509
+23% +$14.2M 0.1% 174
2025
Q2
$56.9M Buy
406,877
+54,131
+15% +$7.59M 0.08% 215
2025
Q1
$51.9M Buy
352,746
+230,784
+189% +$33.4M 0.08% 213
2024
Q4
$16M Sell
121,962
-6,258
-5% -$876K 0.03% 448
2024
Q3
$20M Buy
128,220
+2,981
+2% +$481K 0.03% 397
2024
Q2
$19.5M Buy
125,239
+5,537
+5% +$833K 0.03% 412
2024
Q1
$16.2M Sell
119,702
-2,143
-2% -$284K 0.02% 483
2023
Q4
$16.4M Buy
121,845
+2,644
+2% +$344K 0.03% 462
2023
Q3
$16.1M Sell
119,201
-4,434
-4% -$606K 0.03% 444
2023
Q2
$17.7M Buy
123,635
+3,371
+3% +$496K 0.03% 424
2023
Q1
$16.7M Buy
120,264
+1,513
+1% +$204K 0.03% 428
2022
Q4
$16.1M Sell
118,751
-13,503
-10% -$1.69M 0.03% 430
2022
Q3
$14.5M Buy
132,254
+14,345
+12% +$1.82M 0.03% 442
2022
Q2
$15.6M Buy
117,909
+4,899
+4% +$643K 0.03% 445
2022
Q1
$15M Buy
113,010
+11,906
+12% +$1.43M 0.02% 512
2021
Q4
$11.8M Buy
101,104
+24,165
+31% +$2.84M 0.02% 589
2021
Q3
$9.24M Buy
76,939
+10,013
+15% +$1.17M 0.02% 668
2021
Q2
$8.02M Sell
66,926
-1,311
-2% -$144K 0.01% 713
2021
Q1
$6.79M Sell
68,237
-8,261
-11% -$830K 0.01% 730
2020
Q4
$7.65M Sell
76,498
-26,614
-26% -$2.82M 0.01% 673
2020
Q3
$11.3M Sell
103,112
-20,369
-16% -$2.27M 0.02% 520
2020
Q2
$13.1M Buy
123,481
+19,673
+19% +$2.03M 0.03% 466
2020
Q1
$9.27M Sell
103,808
-29,479
-22% -$2.78M 0.02% 505
2019
Q4
$13.3M Buy
133,287
+97,839
+276% +$9.21M 0.03% 502
2019
Q3
$3.16M Sell
35,448
-5,798
-14% -$503K 0.05% 291
2019
Q2
$3.4M Sell
41,246
-8,705
-17% -$683K 0.06% 271
2019
Q1
$4.04M Sell
49,951
-15,630
-24% -$1.23M 0.07% 251
2018
Q4
$4.98M Sell
65,581
-12,033
-16% -$940K 0.1% 203
2018
Q3
$6.14M Sell
77,614
-5,809
-7% -$439K 0.11% 206
2018
Q2
$5.86M Sell
83,423
-4,689
-5% -$337K 0.11% 214
2018
Q1
$6.16M Buy
88,112
+6,034
+7% +$418K 0.12% 213
2017
Q4
$5.7M Buy
82,078
+5,927
+8% +$400K 0.11% 226
2017
Q3
$5.16M Buy
76,151
+3,875
+5% +$245K 0.1% 238
2017
Q2
$4.93M Buy
72,276
+3,980
+6% +$260K 0.1% 247
2017
Q1
$4.25M Sell
68,296
-9,688
-12% -$564K 0.09% 260
2016
Q4
$4.26M Sell
77,984
-10,811
-12% -$614K 0.09% 255
2016
Q3
$5.83M Buy
88,795
+7,561
+9% +$494K 0.12% 207
2016
Q2
$4.91M Buy
81,234
+7,199
+10% +$418K 0.1% 228
2016
Q1
$4.17M Buy
74,035
+21,035
+40% +$1.26M 0.11% 213
2015
Q4
$3.6M Buy
53,000
+18,779
+55% +$1.23M 0.09% 235
2015
Q3
$2.18M Buy
34,221
+18,030
+111% +$1.19M 0.06% 300
2015
Q2
$1.03M Sell
16,191
-2,897
-15% -$198K 0.03% 379
2015
Q1
$1.31M Sell
19,088
-5,458
-22% -$379K 0.04% 344
2014
Q4
$1.73M Sell
24,546
-6,477
-21% -$464K 0.05% 302
2014
Q3
$2.22M Sell
31,023
-29,236
-49% -$2.14M 0.07% 263
2014
Q2
$4.48M Sell
60,259
-22,620
-27% -$1.64M 0.13% 188
2014
Q1
$5.38M Sell
82,879
-3,264
-4% -$211K 0.17% 149
2013
Q4
$5.12M Buy
86,143
+5,676
+7% +$308K 0.16% 156
2013
Q3
$4.18M Buy
80,467
+3,324
+4% +$167K 0.15% 176
2013
Q2
$3.65M Buy
+77,143
New +$3.93M 0.14% 184

Other funds holding AZN

Truist Financial's AZN Position: Q1 2026 in Review

Truist Financial reduced its AstraZeneca (AZN) stake by 2% in Q1 2026, selling an estimated $2.93M and leaving 754,121 shares worth $149M. The position accounts for 0.2% of the portfolio, ranked #98.

Truist Financial first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Truist Financial held 754,121 shares of AstraZeneca worth $149M as of Q1 2026.
  • Truist Financial sold 15,219 AstraZeneca shares in Q1 2026, an estimated $2.93M.
  • AstraZeneca made up 0.2% of Truist Financial's portfolio in Q1 2026, its #98 holding.
  • Truist Financial first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.